Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0QH9K)

• Drug Name: FS118 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Advanced cancer	2A00-2F9Z	Phase 1	[1]
Advanced malignancy	2A00-2F9Z	Phase 1	[2]

• Cross-matching ID: TTD Drug ID: DM0QH9K

Molecule-Related Drug Atlas

Drug(s) Targeting Lymphocyte activation gene 3 protein (LAG3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Relatlimab	DM28AZV	Melanoma	2C30	Approved	[3]
Anti-LAG3	DMJO402	Gastric adenocarcinoma	2B72	Phase 2	[4]
BMS-986016	DMDCHM7	Hematologic tumour	2B33.Y	Phase 1/2	[5]
IMP-321	DM18ZLW	Allergy	4A80-4A85	Phase 1/2	[6]
Favezelimab	DMYAIE2	Non-hodgkin lymphoma	2B33.5	Phase 1/2	[7]
XmAb22841	DMQB3HD	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
RG6139	DMJFM3O	Solid tumour/cancer	2A00-2F9Z	Phase 1	[9]
ADPT01	DMS6DPF	Breast cancer	2C60-2C65	Phase 1	[10]
IMP-701	DMXSMF9	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
GSK2831781	DMC47M9	Autoimmune disease	4A40-4A45	Phase 1	[12]

Drug(s) Targeting Programmed cell death 1 ligand 1 (PD-L1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avelumab	DMSZLJR	Merkel cell carcinoma	2C34	Approved	[13]
Durvalumab	DM4PVDY	Urothelial carcinoma	2C92.0	Approved	[14]
RG-7446	DM69XMQ	Urothelial carcinoma	2C92.0	Approved	[15]
Bavencio	DMU9C8F	Merkel cell carcinoma	2C34	Approved	[16]
Atezolizumab	DMMF8U0	Non-small-cell lung cancer	2C25	Approved	[17]
Sugemalimab	DMH5YQ3	Non-small-cell lung cancer	2C25	Approved in China	[18]
KN046	DMSDBPG	Non-small-cell lung cancer	2C25.Y	Phase 3	[19]
MEDI4736	DM5X849	Solid tumour/cancer	2A00-2F9Z	Phase 3	[20]
MPDL-3280A	DM9K3LM	Melanoma	2C30	Phase 3	[21]
CS1001	DMSY0NE	Non-small-cell lung cancer	2C25	Phase 3	[22]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lymphocyte activation gene 3 protein (LAG3)	TTNVXAW	LAG3_HUMAN	Not Available	[1]
Programmed cell death 1 ligand 1 (PD-L1)	TT8ZLTI	PD1L1_HUMAN	Not Available	[1]

References

• [1] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway.J Med Chem. 2019 Feb 28;62(4):1715-1730.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761234
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015 March; 7(2): 85-96.
• [6] A soluble form of lymphocyte activation gene-3 (IMP321) induces activation of a large range of human effector cytotoxic cells. J Immunol. 2007 Sep 15;179(6):4202-11.
• [7] A first-in-human study of the anti-LAG-3 antibody favezelimab plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer. ESMO Open. 2022 Dec;7(6):100639.
• [8] Clinical pipeline report, company report or official report of Xencor.
• [9] Clinical pipeline report, company report or official report of Genentech.
• [10] Clinical pipeline report, company report or official report of Novartis.
• [11] IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study. J Immune Based Ther Vaccines. 2007 Mar 29;5:5.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells. Cancer Immunol Res. 2015 Oct;3(10):1148-57.
• [14] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [15] PD-1 as a potential target in cancer therapy. Cancer Med. 2013 October; 2(5): 662-673.
• [16] ClinicalTrials.gov (NCT03403777) Avelumab in Refractory Testicular Germ Cell Cancer.. U.S. National Institutes of Health.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [18] Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
• [19] Clinical pipeline report, company report or official report of Alphamab Oncology.
• [20] National Cancer Institute Drug Dictionary (drug id 740856).
• [21] Targeted immunotherapy for non-small cell lung cancer. World J Clin Oncol. 2014 May 10; 5(2): 39-47.
• [22] GEMSTONE-301: a phase III clinical trial of CS1001 as consolidation therapy in patients with locally advanced/unresectable (stage III) non-small cell lung cancer (NSCLC) who did not have disease progression after prior concurrent/sequential chemoradiotherapy. Transl Lung Cancer Res. 2020 Oct;9(5):2008-2015.